drugset / Trial / NCT03185481

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT03185481

Phase 2 Terminated 5 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Timeline

Start
2017-07-06
Primary completion
2017-10-24
Completion
2017-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule 7 mg
Subject Tavapadon Small molecule 15 mg

Indications